To verify whether modification of the SASP caused by TRPC3 downregulation could contribute to the acquisition of a chemotherapy-resistant phenotype, we assessed the effect of SASP secreted by CAFs on prostate cancer cells. This evidence concerns the gene TRPC3 and prostate carcinoma.